2663 related articles for article (PubMed ID: 7675773)
1. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J
Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.
Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M
Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933
[TBL] [Abstract][Full Text] [Related]
4. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
7. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2].
Villaseca M; Araya JC; Roa I; Roa JC
Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880
[TBL] [Abstract][Full Text] [Related]
8. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma.
Girod SC; Pfeiffer P; Ries J; Pape HD
Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452
[TBL] [Abstract][Full Text] [Related]
9. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of biomarkers in malignant melanoma.
Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
15. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
16. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities of p53 and p110RB tumor suppressor gene expression in human soft tissue tumors: correlations with cell proliferation and tumor grade.
Wang J; Coltrera MD; Gown AM
Mod Pathol; 1995 Oct; 8(8):837-42. PubMed ID: 8552572
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis.
Girod SC; Cesarz D; Fischer U; Krueger GR
Anticancer Res; 1995; 15(4):1453-7. PubMed ID: 7654034
[TBL] [Abstract][Full Text] [Related]
19. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
